Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (392 views visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 2.767, 5-year impact factor Impact factor a 5 anni: 3.497
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0037318794&partnerID=40&md5=e9d967b9f008d2e531a080c7e96d6392
Keywords Parole chiave: Angiopeptin, Glucose, Growth Hormone, Insulin, Octreotide, Somatomedin C, Somatostatin Derivative, Acromegaly, Adult, Angiography, Article, Cardiomyopathy, Clinical Article, Controlled Study, Diastole, Disease Control, Disease Duration, Drug Efficacy, Early Diagnosis, Echocardiography, Exercise Tolerance, Female, Follow Up, Heart Left Ventricle Ejection Fraction, Heart Left Ventricle Function, Heart Left Ventricle Hypertrophy, Hemodynamics, Human, Oral Glucose Tolerance Test, Priority Journal, Remission, Time Series Analysis, Treatment Outcome, Age Factors, Antineoplastic Agents, Case-Control Studies, Chi-Square Distribution, Delayed-Action Preparations, Doppler, Pulsed, Exercise Test, Left Ventricular, Immunoradiometric Assay, Insulin-Like Growth Factor I, Middle Aged, Prospective Studies, Radionuclide Angiography, Statistics, Nonparametric, Stroke Volume, Time Factors,
Affiliations Affiliazioni:
*** IBB - CNR ***
Dept. Molec./Clin. Endocrinol./O., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Dept. Biomorphological/Funct. Sci., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Int. Med. I 'Federico II' Univ. N., Pozzilli, Italy
Sci. Inst. for Res./Care Neuromed, Pozzilli, Italy
Dept. Molec. /Clin. Endocrinol. /O., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Sci. Inst. for Res. /Care Neuromed, Pozzilli, Italy
References Riferimenti:
Baldelli, R., Ferretti, E., Jaffrain-Rea, M.L., Iacobellis, G., Minniti, G., Caracciolo, B., Moroni, C., Tamburrano, G., Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients (1999) Journal of Clinical Endocrinology and Metabolism, 84, pp. 575-53
Bates, A.S., Van't Hoff, W., Jones, J.M., Clayton, R.N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Bengtsson, B., Eden, S., Ernest, I., Oden, A., Sjogren, B., Epidemiology and long term survival in acromegaly (1988) Acta Medica Scandinavica, 223, pp. 327-335
Colao, A., Baldelli, R., Marzullo, P., Ferretti, E., Ferone, D., Gargiulo, P., Petretta, M., Liuzzi, A., Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 193-199
Colao, A., Cuocolo, A., Marzullo, P., Nicolai, E., Ferone, D., Della Morte, A.M., Pivonello, R., Lombardi, G., Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance (2001) Journal of Clinical Endocrinology Metabolism, 86, pp. 1551-1557
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) Journal of Clinical Endocrinology Metabolism, 81, pp. 2356-2362
Colao, A., Lombardi, G., Growth hormone and prolactin excess (1998) Lancet, 352, pp. 1455-1461
Colao, A., Marzullo, P., Di Somma, C., Lombardi, G., Growth hormone and the heart (2001) Clinical Endocrinology, 54, pp. 137-154
Colao, A., Merola, B., Ferone, D., Lombardi, G., Extensive personal experience: Acromegaly (1997) Journal of Clinical Endocrinology and Metabolism, 82, pp. 2777-2781
Colao, A., Spinelli, L., Cuocolo, A., Spiezia, S., Pivonello, R., Di Somma, C., Bonaduce, D., Lombardi, G., Cardiovascular consequences of early-onset growth hormone excess (2002) Journal of Clinical Endocrinology Metabolism, 87, pp. 3097-3104
Fazio, S., Cittadini, A., Biondi, B., Palmieri, E.A., Riccio, G., Bonè, F., Oliviero, U., Saccà, L., Cardiovascular effects of short-term growth hormone hypersecretion (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 179-182
Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Melmed, S., Criteria for cure of acromegaly: A consensus statement (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 526-529
Hayward, R.P., Emanuel, R.W., Nabarro, J.D.N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M.R., Bradfield, J.Y., Herrmann, G.R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Hradec, J., Kral, J., Janota, T., Krsek, M., Hana, V., Marek, J., Malik, M., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) (1999) American Journal of Cardiology, 83, pp. 1506-1509
Lancranjan, I., Atkinson, A.B., Results of a European multicentre study with sandostatin LAR in acromegalic patients (1999) Pituitary, 1, pp. 105-114
Lie, J.T., Grossman, S.J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M.J., Barkan, A.L., Buda, A.J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
López-Velasco, R., Escobar-Morreale, H.F., Vega, B., Villa, E., Sancho, J.M., Moya-Mur, J.L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W.L., Jr., Sherman, B.M., Roth, J., Gorden, P., Kahn, C.R., Roberts, W.C., Frommer, P.L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Merola, B., Cittadini, A., Colao, A., Ferone, D., Fazio, S., Sabatini, D., Biondi, B., Lombardi, G., Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly (1993) Journal of Clinical Endocrinology and Metabolism, 77, pp. 790-793
Minniti, G., Jaffrain-Rea, M.L., Moroni, C., Baldelli, R., Ferretti, E., Cassone, R., Gulino, A., Tamburrano, G., Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics (1998) Clinical Endocrinology, 49, pp. 101-106
Morvan, D., Komajda, M., Grimaldi, A., Turpin, G., Grosgogeat, Y., Cardiac hypertrophy and function in asymptomatic acromegaly (1991) European Heart Journal, 12, pp. 666-672
Orme, S.M., McNally, R.J., Cartwright, R.A., Belchetz, P.E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Pereira, J., Rodriguez-Puras, M.J., Leal-Cerro, A., Martinez, A., Garcial-Luna, P.P., Gavilan, I., Pumar, A., Astorga, R., Acromegalic cardiopathy improves after treatment with increasing doses of octreotide (1991) Journal of Endocrinological Investigation, 14, pp. 17-23
Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J., Ibbertson, H.K., Determinants of clinical outcome and survival in acromegaly (1994) Clinical Endocrinology, 41, pp. 95-102
Sahn, D.J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D.D., Henry, W.L., Eastman, R.C., Borer, J.S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R.C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Thuesen, L., Christensen, S.E., Weeke, J., Orskov, H., Henningsen, P., A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? (1988) Acta Medica Scandinavica, 223, pp. 337-343
Tokgözoglu, S.L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A.D., Hill, D.M., Lowy, C., Fraser, T.R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Bates, A. S., Van't Hoff, W., Jones, J. M., Clayton, R. N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Hayward, R. P., Emanuel, R. W., Nabarro, J. D. N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M. R., Bradfield, J. Y., Herrmann, G. R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Lie, J. T., Grossman, S. J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M. J., Barkan, A. L., Buda, A. J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
L pez-Velasco, R., Escobar-Morreale, H. F., Vega, B., Villa, E., Sancho, J. M., Moya-Mur, J. L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W. L., Jr., Sherman, B. M., Roth, J., Gorden, P., Kahn, C. R., Roberts, W. C., Frommer, P. L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Orme, S. M., McNally, R. J., Cartwright, R. A., Belchetz, P. E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Sahn, D. J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D. D., Henry, W. L., Eastman, R. C., Borer, J. S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R. C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Tokg zoglu, S. L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A. D., Hill, D. M., Lowy, C., Fraser, T. R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 2.767, 5-year impact factor Impact factor a 5 anni: 3.497
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0037318794&partnerID=40&md5=e9d967b9f008d2e531a080c7e96d6392
Keywords Parole chiave: Angiopeptin, Glucose, Growth Hormone, Insulin, Octreotide, Somatomedin C, Somatostatin Derivative, Acromegaly, Adult, Angiography, Article, Cardiomyopathy, Clinical Article, Controlled Study, Diastole, Disease Control, Disease Duration, Drug Efficacy, Early Diagnosis, Echocardiography, Exercise Tolerance, Female, Follow Up, Heart Left Ventricle Ejection Fraction, Heart Left Ventricle Function, Heart Left Ventricle Hypertrophy, Hemodynamics, Human, Oral Glucose Tolerance Test, Priority Journal, Remission, Time Series Analysis, Treatment Outcome, Age Factors, Antineoplastic Agents, Case-Control Studies, Chi-Square Distribution, Delayed-Action Preparations, Doppler, Pulsed, Exercise Test, Left Ventricular, Immunoradiometric Assay, Insulin-Like Growth Factor I, Middle Aged, Prospective Studies, Radionuclide Angiography, Statistics, Nonparametric, Stroke Volume, Time Factors,
Affiliations Affiliazioni:
*** IBB - CNR ***
Dept. Molec./Clin. Endocrinol./O., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Dept. Biomorphological/Funct. Sci., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Int. Med. I 'Federico II' Univ. N., Pozzilli, Italy
Sci. Inst. for Res./Care Neuromed, Pozzilli, Italy
Dept. Molec. /Clin. Endocrinol. /O., Nucl. Med. Ctr. Natl. Cncl. Res., Pozzilli, Italy
Sci. Inst. for Res. /Care Neuromed, Pozzilli, Italy
References Riferimenti:
Baldelli, R., Ferretti, E., Jaffrain-Rea, M.L., Iacobellis, G., Minniti, G., Caracciolo, B., Moroni, C., Tamburrano, G., Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients (1999) Journal of Clinical Endocrinology and Metabolism, 84, pp. 575-53
Bates, A.S., Van't Hoff, W., Jones, J.M., Clayton, R.N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Bengtsson, B., Eden, S., Ernest, I., Oden, A., Sjogren, B., Epidemiology and long term survival in acromegaly (1988) Acta Medica Scandinavica, 223, pp. 327-335
Colao, A., Baldelli, R., Marzullo, P., Ferretti, E., Ferone, D., Gargiulo, P., Petretta, M., Liuzzi, A., Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 193-199
Colao, A., Cuocolo, A., Marzullo, P., Nicolai, E., Ferone, D., Della Morte, A.M., Pivonello, R., Lombardi, G., Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance (2001) Journal of Clinical Endocrinology Metabolism, 86, pp. 1551-1557
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) Journal of Clinical Endocrinology Metabolism, 81, pp. 2356-2362
Colao, A., Lombardi, G., Growth hormone and prolactin excess (1998) Lancet, 352, pp. 1455-1461
Colao, A., Marzullo, P., Di Somma, C., Lombardi, G., Growth hormone and the heart (2001) Clinical Endocrinology, 54, pp. 137-154
Colao, A., Merola, B., Ferone, D., Lombardi, G., Extensive personal experience: Acromegaly (1997) Journal of Clinical Endocrinology and Metabolism, 82, pp. 2777-2781
Colao, A., Spinelli, L., Cuocolo, A., Spiezia, S., Pivonello, R., Di Somma, C., Bonaduce, D., Lombardi, G., Cardiovascular consequences of early-onset growth hormone excess (2002) Journal of Clinical Endocrinology Metabolism, 87, pp. 3097-3104
Fazio, S., Cittadini, A., Biondi, B., Palmieri, E.A., Riccio, G., Bonè, F., Oliviero, U., Saccà, L., Cardiovascular effects of short-term growth hormone hypersecretion (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 179-182
Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Melmed, S., Criteria for cure of acromegaly: A consensus statement (2000) Journal of Clinical Endocrinology and Metabolism, 85, pp. 526-529
Hayward, R.P., Emanuel, R.W., Nabarro, J.D.N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M.R., Bradfield, J.Y., Herrmann, G.R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Hradec, J., Kral, J., Janota, T., Krsek, M., Hana, V., Marek, J., Malik, M., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) (1999) American Journal of Cardiology, 83, pp. 1506-1509
Lancranjan, I., Atkinson, A.B., Results of a European multicentre study with sandostatin LAR in acromegalic patients (1999) Pituitary, 1, pp. 105-114
Lie, J.T., Grossman, S.J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M.J., Barkan, A.L., Buda, A.J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
López-Velasco, R., Escobar-Morreale, H.F., Vega, B., Villa, E., Sancho, J.M., Moya-Mur, J.L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W.L., Jr., Sherman, B.M., Roth, J., Gorden, P., Kahn, C.R., Roberts, W.C., Frommer, P.L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Merola, B., Cittadini, A., Colao, A., Ferone, D., Fazio, S., Sabatini, D., Biondi, B., Lombardi, G., Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly (1993) Journal of Clinical Endocrinology and Metabolism, 77, pp. 790-793
Minniti, G., Jaffrain-Rea, M.L., Moroni, C., Baldelli, R., Ferretti, E., Cassone, R., Gulino, A., Tamburrano, G., Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics (1998) Clinical Endocrinology, 49, pp. 101-106
Morvan, D., Komajda, M., Grimaldi, A., Turpin, G., Grosgogeat, Y., Cardiac hypertrophy and function in asymptomatic acromegaly (1991) European Heart Journal, 12, pp. 666-672
Orme, S.M., McNally, R.J., Cartwright, R.A., Belchetz, P.E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Pereira, J., Rodriguez-Puras, M.J., Leal-Cerro, A., Martinez, A., Garcial-Luna, P.P., Gavilan, I., Pumar, A., Astorga, R., Acromegalic cardiopathy improves after treatment with increasing doses of octreotide (1991) Journal of Endocrinological Investigation, 14, pp. 17-23
Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J., Ibbertson, H.K., Determinants of clinical outcome and survival in acromegaly (1994) Clinical Endocrinology, 41, pp. 95-102
Sahn, D.J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D.D., Henry, W.L., Eastman, R.C., Borer, J.S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R.C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Thuesen, L., Christensen, S.E., Weeke, J., Orskov, H., Henningsen, P., A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? (1988) Acta Medica Scandinavica, 223, pp. 337-343
Tokgözoglu, S.L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A.D., Hill, D.M., Lowy, C., Fraser, T.R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Bates, A. S., Van't Hoff, W., Jones, J. M., Clayton, R. N., An audit of outcome of treatment in acromegaly (1993) Quarterly Journal of Medicine, 86, pp. 293-299
Hayward, R. P., Emanuel, R. W., Nabarro, J. D. N., Acromegalic heart disease: Influence of treatment of the acromegaly on the heart (1987) Quarterly Journal of Medicine, 62, pp. 41-58
Hejtmancik, M. R., Bradfield, J. Y., Herrmann, G. R., Acromegaly and the heart: A clinical and pathologic study (1951) Annals of Internal Medicine, 34, pp. 1445-1456
Lie, J. T., Grossman, S. J., Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients (1980) American Heart Journal, 100, pp. 41-52
Lim, M. J., Barkan, A. L., Buda, A. J., Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion (1992) Annals of Internal Medicine, 117, pp. 719-726
L pez-Velasco, R., Escobar-Morreale, H. F., Vega, B., Villa, E., Sancho, J. M., Moya-Mur, J. L., Garcia-Robles, R., Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension (1997) Journal of Clinical Endocrinology Metabolism, 82, pp. 1047-1053
McGuffin W. L., Jr., Sherman, B. M., Roth, J., Gorden, P., Kahn, C. R., Roberts, W. C., Frommer, P. L., Acromegaly and cardiovascular disorders: A prospective study (1974) Annals of Internal Medicine, 81, pp. 11-18
Orme, S. M., McNally, R. J., Cartwright, R. A., Belchetz, P. E., Mortality and cancer incidence in acromegaly: A retrospective cohort study (1998) Journal of Clinical Endocrinology and Metabolism, 83, pp. 2730-2734. , United Kingdom Acromegaly Study Group
Sahn, D. J., De Maria, A., Kissio, J., Weyman, A., The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiography measurements (1978) Circulation, 58, pp. 1072-1083
Savage, D. D., Henry, W. L., Eastman, R. C., Borer, J. S., Gorden, P., Echocardiographic assessment of cardiac anatomy and function in patients (1979) American Journal of Medicine, 67, pp. 823-829
Smallridge, R. C., Rajfer, S., Davia, J., Schaaf, M., Acromegaly and the heart. An echocardiographic study (1979) American Journal of Medicine, 66, pp. 22-27
Tokg zoglu, S. L., Erbas, T., Aytemir, K., Akalin, S., Kes, S., Oram, E., Effects of octreotide on left ventricular mass in acromegaly (1994) American Journal of Cardiology, 74, pp. 1072-1074
Wright, A. D., Hill, D. M., Lowy, C., Fraser, T. R., Mortality in acromegaly (1970) Quarterly Journal of Medicine, 39, pp. 1-16
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
BACKGROUND: Cardiovascular disease is the most frequent cause of death of patients with acromegaly. AIM To investigate whether young patients with a presumed short disease duration are more likely to reverse the acromegalic cardiomyopathy than older patients with longer disease duration. DESIGN: An open prospective design. PATIENTS: Ten young (aged < 40 years), and 12 middle-aged (41-59 years) patients with active acromegaly well controlled after 12 months of treatment with the depot formulation of octreotide (OCT-LAR); 22 sex- and age-matched healthy subjects as controls. METHODS: Left ventricular (LV) mass (LVM) by echocardiography and performance by equilibrium radionuclide angiography were measured before and after 12 months of OCT-LAR treatment. RESULTS: At study entry, none of the controls and 14 patients (63.4%) of whom six were young (χ2 = 17.7; P < 0.0001) had LV hypertrophy (LVH); none of the controls and four patients of whom one was young had insufficient LV ejection fraction (LVEF) at rest (< 50%); one control and 13 patients (59.1%) of whom five were young (χ2= 12.7; P < 0.0001) had inadequate LVEF at peak exercise (ΔLVEF; < 5% increase of baseline). After 12 months, no change in haemodynamic and diastolic parameters was observed in both groups, except for a significant decrease in heart rate at peak exercise in young patients (P < 0.0001). The LVM index decreased significantly in both young (124.4 ± 5.8 vs. 103.4 ± 3.9 g/m2; P = 0.01) and middle-aged patients (140.9 ± 7.9 vs. 117.8 ± 6.6 g/m2; P= 0.03). LVH disappeared in 10 of 14 patients (71.4%): all six young and four of eight middle-aged patients (50%). LVEF at rest and at peak exercise increased significantly in both groups but ΔLVEF increased significantly only in young patients (1.5 ± 2.9 vs. 13.7 ± 5.2%, P= 0.04); it normalized in nine of 13 patients (69.2%), four of five young (80%) and four of eight middle-aged patients (50%). Exercise capacity (82.5 ± 5.3 vs. 110.0 ± 5.5 W, P= 0.005) and duration (7.3 ± 0.3 vs. 9.9 ± 0.4 min, P = 0.0003) also increased only in young patients. CONCLUSIONS: The acromegalic cardiomyopathy is reversed in most young patients with short disease duration and achieving disease control after OCT-LAR treatment for 12 months, indicating that early diagnosis and effective treatment are essential.
BACKGROUND: Cardiovascular disease is the most frequent cause of death of patients with acromegaly. AIM To investigate whether young patients with a presumed short disease duration are more likely to reverse the acromegalic cardiomyopathy than older patients with longer disease duration. DESIGN: An open prospective design. PATIENTS: Ten young (aged < 40 years), and 12 middle-aged (41-59 years) patients with active acromegaly well controlled after 12 months of treatment with the depot formulation of octreotide (OCT-LAR); 22 sex- and age-matched healthy subjects as controls. METHODS: Left ventricular (LV) mass (LVM) by echocardiography and performance by equilibrium radionuclide angiography were measured before and after 12 months of OCT-LAR treatment. RESULTS: At study entry, none of the controls and 14 patients (63.4%) of whom six were young (χ2 = 17.7; P < 0.0001) had LV hypertrophy (LVH); none of the controls and four patients of whom one was young had insufficient LV ejection fraction (LVEF) at rest (< 50%); one control and 13 patients (59.1%) of whom five were young (χ2= 12.7; P < 0.0001) had inadequate LVEF at peak exercise (ΔLVEF; < 5% increase of baseline). After 12 months, no change in haemodynamic and diastolic parameters was observed in both groups, except for a significant decrease in heart rate at peak exercise in young patients (P < 0.0001). The LVM index decreased significantly in both young (124.4 ± 5.8 vs. 103.4 ± 3.9 g/m2; P = 0.01) and middle-aged patients (140.9 ± 7.9 vs. 117.8 ± 6.6 g/m2; P= 0.03). LVH disappeared in 10 of 14 patients (71.4%): all six young and four of eight middle-aged patients (50%). LVEF at rest and at peak exercise increased significantly in both groups but ΔLVEF increased significantly only in young patients (1.5 ± 2.9 vs. 13.7 ± 5.2%, P= 0.04); it normalized in nine of 13 patients (69.2%), four of five young (80%) and four of eight middle-aged patients (50%). Exercise capacity (82.5 ± 5.3 vs. 110.0 ± 5.5 W, P= 0.005) and duration (7.3 ± 0.3 vs. 9.9 ± 0.4 min, P = 0.0003) also increased only in young patients. CONCLUSIONS: The acromegalic cardiomyopathy is reversed in most young patients with short disease duration and achieving disease control after OCT-LAR treatment for 12 months, indicating that early diagnosis and effective treatment are essential.
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
| ▼ Clinical Oncology |
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, Cianflone A, Marsili A, Puorro G, Sacca F, Russo CV, De Luca Picione C, Ausiello F, Colao A, Brescia Morra V
* Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon beta-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis (243 visite)
Eur J Neurol (ISSN: 1351-5101, 1468-1331electronic, 1351-5101linking), 2017 Feb; 24(2): 446-449.
Impact Factor: 4.621
Dettagli Esporta in BibTeX Esporta in EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (256 visite)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
Dettagli Esporta in BibTeX Esporta in EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (302 visite)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, Di Pietro P, Pappalardo G, Attanasio F, Chiechio S, Bagnoli S, Nacmias B, Sorbi S, Vigneri R, Rizzarelli E, Nicoletti F, Copani A
* Monomeric ss-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons (471 visite)
Front Cell Neurosci (ISSN: 1662-5102), 2015 Aug 7; 9(AUGUST): 297-297.
Impact Factor: 4.609
Dettagli Esporta in BibTeX Esporta in EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (461 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
Dettagli Esporta in BibTeX Esporta in EndNote
Milardi D, Sciacca MF, Randazzo L, Raudino A, La Rosa C
* The role of calcium, lipid membranes and islet amyloid polypeptide in the onset of type 2 diabetes: Innocent bystanders or partners in a crime? (396 visite)
Front Endocrinol (ISSN: 1664-2392, 1664-2392linking, 1664-2392print), 2014; 5(DEC): 216-216.
Impact Factor: 3.675
Dettagli Esporta in BibTeX Esporta in EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1315 visite)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (243 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (362 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
Dettagli Esporta in BibTeX Esporta in EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (329 visite)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A
* Beta-Amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease (545 visite)
Mol Neurobiol (ISSN: 0893-7648), 2012 Dec; 46(3): 605-613.
Impact Factor: 5.471
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (248 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
Dettagli Esporta in BibTeX Esporta in EndNote
Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M
* A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results (624 visite)
J Neurol (ISSN: 1432-1459, 0340-5354, 1432-1459electronic), 2012 Jan; 259(1): 132-138.
Impact Factor: 3.578
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (464 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
Dettagli Esporta in BibTeX Esporta in EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (405 visite)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
Dettagli Esporta in BibTeX Esporta in EndNote
Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Vacca G, Liuzzi R, Amato L, Orefice G, Colao A, Brescia Morra V
* Growth Hormone Axis In Early Multiple Sclerosis Patients Before And After 2 Years Treatment With Interferon Beta-1b - An Interim Analysis (243 visite)
Proceedings Of The Xlii Meeting Of The Italian Society Of Neurology, 2011; nd: 360-360.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (539 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A
* Beta-Amyloid Monomers Are Neuroprotective (544 visite)
J Neurosci (ISSN: 1529-2401, 0270-6474), 2009 Sep 26; 29(34): 10582-10587.
Impact Factor: 3.669
Dettagli Esporta in BibTeX Esporta in EndNote
Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del Forno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L
* Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction (509 visite)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2009 Sep; 94(9): 3329-3336.
Impact Factor: 6.202
Dettagli Esporta in BibTeX Esporta in EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Double-Blind, Placebo-Controlled, Randomized Trial of Growth Hormone as Add-On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: Preliminary MRS, Hormonal, and Population Analysis (366 visite)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 72(11): N/D-N/D.
Impact Factor: 8.172
Dettagli Esporta in BibTeX Esporta in EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Randomized Trial of Growth Hormone as Add. On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis (294 visite)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 76(9): N/D-N/D.
Impact Factor: 8.172
Dettagli Esporta in BibTeX Esporta in EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (341 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
Dettagli Esporta in BibTeX Esporta in EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (783 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
Dettagli Esporta in BibTeX Esporta in EndNote
Cittadini A, Monti MG, Castiello MC, D'Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, Saccà L
* Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury (361 visite)
J Thromb Haemost Journal Of Thrombosis And Haemostasis (ISSN: 1538-7933), 2009; 7(11): 1920-1928.
Impact Factor: 6.069
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (469 visite)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
Dettagli Esporta in BibTeX Esporta in EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (334 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (386 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
Migliore T, Parrella LS, Caputi A, Silvestri N, Romano R, Pace L, Imbriaco M, Losi MA, Betocchi S
* Pathogenesis of hypertrophic cardiomyopathy. Impact of growth factors on left ventricular anatomy (338 visite)
Minerva Cardioangiol (ISSN: 0026-4725), 2008 Feb; 56(1): 13-20.
Impact Factor: 0.481
Dettagli Esporta in BibTeX Esporta in EndNote
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R
* The role of insulin receptors and IGF-I receptors in cancer and other diseases (1521 visite)
Archives Of Physiology And Biochemistry (ISSN: 1381-3455), 2008 Feb; 114(1): 23-37.
Impact Factor: 2.028
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Acampa W, Spiezia S, Rota F, Savanelli MC, Lombardi G
* Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency (399 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2005 Sep; 90(9): 5146-5155.
Impact Factor: 6.02
Dettagli Esporta in BibTeX Esporta in EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (312 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
Dettagli Esporta in BibTeX Esporta in EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (278 visite)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G
* The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: An observational, case-control study (270 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2004 Dec; 89(12): 5998-6004.
Impact Factor: 5.778
Dettagli Esporta in BibTeX Esporta in EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (425 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
Dettagli Esporta in BibTeX Esporta in EndNote
Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A, Acampa W, Bonaduce D, Colao A, Cuocolo A
* Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly (360 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Sep; 88(9): 4105-4109.
Impact Factor: 5.873
Dettagli Esporta in BibTeX Esporta in EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (312 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (341 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G
* The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: A 12-month prospective study (334 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Mar; 87(3): 1088-1093.
Impact Factor: 5.199
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients, with GH deficiency (300 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 May; 86(5): 1874-1881.
Impact Factor: 5.16
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (269 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (338 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
Dettagli Esporta in BibTeX Esporta in EndNote
Marzullo P, Cuocolo A, Ferone D, Pivonello R, Salvatore M, Lombardi G, Colao A
Cardiac effect of thyrotoxicosis in acromegaly (356 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Apr; 85(4): 1426-1432.
Impact Factor: 5.447
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Pivonello R, Nicolai E, Salvatore M, Lombardi G
Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study (264 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2000 Apr; 52(4): 447-455.
Impact Factor: 2.922
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Nicolai E, Lucci R, Salvatore M, Lombardi G
Impaired cardiac performance in elderly patients with growth hormone deficiency (285 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Nov; 84(11): 3950-3955.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A, Petretta M, Salvatore M, Lombardi G
Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study (250 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 May; 84(5): 1518-1523.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (358 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (292 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (396 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
Dettagli Esporta in BibTeX Esporta in EndNote
Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G
Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency (303 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 1998 Feb; 48(2): 137-143.
Impact Factor: 3.101
Dettagli Esporta in BibTeX Esporta in EndNote
Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas (287 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Impact Factor: 5.641
Dettagli Esporta in BibTeX Esporta in EndNote
Lombardi G, Colao A, Cuocolo A, Longobardi S, Di Somma C, Orio F, Merola B, Nicolai E, Salvatore M
Cardiological aspects of growth hormone and insulin-like growth factor- (311 visite)
J Pediatr Endocrinol Metab (ISSN: 0334-018x), 1997 Nov; 10(6): 553-560.
Impact Factor: 0.481
Dettagli Esporta in BibTeX Esporta in EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (309 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (308 visite)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
Dettagli Esporta in BibTeX Esporta in EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (204 visite)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (210 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (235 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (258 visite)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Pezzino V, Papa V, Trischitta V, Brunetti A, Goodman PA, Treutelaar MK, Williams JA, Maddux BA, Vigneri R, Goldfine ID
Human insulin receptor radioimmunoassay: Applicability to insulin-resistant states (237 visite)
Am J Physiol Endocrinol Metab (ISSN: 0002-9513), 1989 Sep; 257(3): N/D-N/D.
Impact Factor: 3.116
Dettagli Esporta in BibTeX Esporta in EndNote
59 Records (48 escludendo Abstract e Conferenze).
Impact factor totale: 240.752 (200.304 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 202.844 (168.235 escludendo Abstract e Conferenze).
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, Cianflone A, Marsili A, Puorro G, Sacca F, Russo CV, De Luca Picione C, Ausiello F, Colao A, Brescia Morra V
* Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon beta-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis (243 visite)
Eur J Neurol (ISSN: 1351-5101, 1468-1331electronic, 1351-5101linking), 2017 Feb; 24(2): 446-449.
Impact Factor: 4.621
Dettagli Esporta in BibTeX Esporta in EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (256 visite)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
Dettagli Esporta in BibTeX Esporta in EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (302 visite)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, Di Pietro P, Pappalardo G, Attanasio F, Chiechio S, Bagnoli S, Nacmias B, Sorbi S, Vigneri R, Rizzarelli E, Nicoletti F, Copani A
* Monomeric ss-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons (471 visite)
Front Cell Neurosci (ISSN: 1662-5102), 2015 Aug 7; 9(AUGUST): 297-297.
Impact Factor: 4.609
Dettagli Esporta in BibTeX Esporta in EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (461 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
Dettagli Esporta in BibTeX Esporta in EndNote
Milardi D, Sciacca MF, Randazzo L, Raudino A, La Rosa C
* The role of calcium, lipid membranes and islet amyloid polypeptide in the onset of type 2 diabetes: Innocent bystanders or partners in a crime? (396 visite)
Front Endocrinol (ISSN: 1664-2392, 1664-2392linking, 1664-2392print), 2014; 5(DEC): 216-216.
Impact Factor: 3.675
Dettagli Esporta in BibTeX Esporta in EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1315 visite)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (243 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (362 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
Dettagli Esporta in BibTeX Esporta in EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (329 visite)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A
* Beta-Amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease (545 visite)
Mol Neurobiol (ISSN: 0893-7648), 2012 Dec; 46(3): 605-613.
Impact Factor: 5.471
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (248 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
Dettagli Esporta in BibTeX Esporta in EndNote
Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M
* A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results (624 visite)
J Neurol (ISSN: 1432-1459, 0340-5354, 1432-1459electronic), 2012 Jan; 259(1): 132-138.
Impact Factor: 3.578
Dettagli Esporta in BibTeX Esporta in EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (464 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
Dettagli Esporta in BibTeX Esporta in EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (405 visite)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
Dettagli Esporta in BibTeX Esporta in EndNote
Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Vacca G, Liuzzi R, Amato L, Orefice G, Colao A, Brescia Morra V
* Growth Hormone Axis In Early Multiple Sclerosis Patients Before And After 2 Years Treatment With Interferon Beta-1b - An Interim Analysis (243 visite)
Proceedings Of The Xlii Meeting Of The Italian Society Of Neurology, 2011; nd: 360-360.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (539 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A
* Beta-Amyloid Monomers Are Neuroprotective (544 visite)
J Neurosci (ISSN: 1529-2401, 0270-6474), 2009 Sep 26; 29(34): 10582-10587.
Impact Factor: 3.669
Dettagli Esporta in BibTeX Esporta in EndNote
Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del Forno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L
* Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction (509 visite)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2009 Sep; 94(9): 3329-3336.
Impact Factor: 6.202
Dettagli Esporta in BibTeX Esporta in EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Double-Blind, Placebo-Controlled, Randomized Trial of Growth Hormone as Add-On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: Preliminary MRS, Hormonal, and Population Analysis (366 visite)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 72(11): N/D-N/D.
Impact Factor: 8.172
Dettagli Esporta in BibTeX Esporta in EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Randomized Trial of Growth Hormone as Add. On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis (294 visite)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 76(9): N/D-N/D.
Impact Factor: 8.172
Dettagli Esporta in BibTeX Esporta in EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (341 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
Dettagli Esporta in BibTeX Esporta in EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (783 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
Dettagli Esporta in BibTeX Esporta in EndNote
Cittadini A, Monti MG, Castiello MC, D'Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, Saccà L
* Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury (361 visite)
J Thromb Haemost Journal Of Thrombosis And Haemostasis (ISSN: 1538-7933), 2009; 7(11): 1920-1928.
Impact Factor: 6.069
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (469 visite)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
Dettagli Esporta in BibTeX Esporta in EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (334 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
Dettagli Esporta in BibTeX Esporta in EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (386 visite)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
Dettagli Esporta in BibTeX Esporta in EndNote
Migliore T, Parrella LS, Caputi A, Silvestri N, Romano R, Pace L, Imbriaco M, Losi MA, Betocchi S
* Pathogenesis of hypertrophic cardiomyopathy. Impact of growth factors on left ventricular anatomy (338 visite)
Minerva Cardioangiol (ISSN: 0026-4725), 2008 Feb; 56(1): 13-20.
Impact Factor: 0.481
Dettagli Esporta in BibTeX Esporta in EndNote
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R
* The role of insulin receptors and IGF-I receptors in cancer and other diseases (1521 visite)
Archives Of Physiology And Biochemistry (ISSN: 1381-3455), 2008 Feb; 114(1): 23-37.
Impact Factor: 2.028
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Acampa W, Spiezia S, Rota F, Savanelli MC, Lombardi G
* Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency (399 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2005 Sep; 90(9): 5146-5155.
Impact Factor: 6.02
Dettagli Esporta in BibTeX Esporta in EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (312 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
Dettagli Esporta in BibTeX Esporta in EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (278 visite)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G
* The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: An observational, case-control study (270 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2004 Dec; 89(12): 5998-6004.
Impact Factor: 5.778
Dettagli Esporta in BibTeX Esporta in EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (425 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
Dettagli Esporta in BibTeX Esporta in EndNote
Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A, Acampa W, Bonaduce D, Colao A, Cuocolo A
* Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly (360 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Sep; 88(9): 4105-4109.
Impact Factor: 5.873
Dettagli Esporta in BibTeX Esporta in EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (312 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (341 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G
* The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: A 12-month prospective study (334 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Mar; 87(3): 1088-1093.
Impact Factor: 5.199
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients, with GH deficiency (300 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 May; 86(5): 1874-1881.
Impact Factor: 5.16
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (269 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (338 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
Dettagli Esporta in BibTeX Esporta in EndNote
Marzullo P, Cuocolo A, Ferone D, Pivonello R, Salvatore M, Lombardi G, Colao A
Cardiac effect of thyrotoxicosis in acromegaly (356 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Apr; 85(4): 1426-1432.
Impact Factor: 5.447
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Pivonello R, Nicolai E, Salvatore M, Lombardi G
Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study (264 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2000 Apr; 52(4): 447-455.
Impact Factor: 2.922
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Nicolai E, Lucci R, Salvatore M, Lombardi G
Impaired cardiac performance in elderly patients with growth hormone deficiency (285 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Nov; 84(11): 3950-3955.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A, Petretta M, Salvatore M, Lombardi G
Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study (250 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 May; 84(5): 1518-1523.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (358 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
Dettagli Esporta in BibTeX Esporta in EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (292 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (396 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
Dettagli Esporta in BibTeX Esporta in EndNote
Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G
Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency (303 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 1998 Feb; 48(2): 137-143.
Impact Factor: 3.101
Dettagli Esporta in BibTeX Esporta in EndNote
Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas (287 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Impact Factor: 5.641
Dettagli Esporta in BibTeX Esporta in EndNote
Lombardi G, Colao A, Cuocolo A, Longobardi S, Di Somma C, Orio F, Merola B, Nicolai E, Salvatore M
Cardiological aspects of growth hormone and insulin-like growth factor- (311 visite)
J Pediatr Endocrinol Metab (ISSN: 0334-018x), 1997 Nov; 10(6): 553-560.
Impact Factor: 0.481
Dettagli Esporta in BibTeX Esporta in EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (309 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (308 visite)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
Dettagli Esporta in BibTeX Esporta in EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (204 visite)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (210 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (235 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (258 visite)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Pezzino V, Papa V, Trischitta V, Brunetti A, Goodman PA, Treutelaar MK, Williams JA, Maddux BA, Vigneri R, Goldfine ID
Human insulin receptor radioimmunoassay: Applicability to insulin-resistant states (237 visite)
Am J Physiol Endocrinol Metab (ISSN: 0002-9513), 1989 Sep; 257(3): N/D-N/D.
Impact Factor: 3.116
Dettagli Esporta in BibTeX Esporta in EndNote
59 Records (48 escludendo Abstract e Conferenze).
Impact factor totale: 240.752 (200.304 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 202.844 (168.235 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:11
392 views visite. Last view on Ultima visita in data Sunday 18 July 2021, 22:43:17
ibb.cnr.it